Arvin Narula, MD
Interventional Cardiology · San Diego, CANPI 1144535709
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (37.5%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Shockwave Medical, Inc at 44.5% of the total. 2025 is the largest year on record at $48,621, 6.1 times the $7,991 reported in 2019. Among interventional cardiology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 905 payments — averaging $179.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shockwave Medical, Inc$73K
- Edwards Lifesciences$23K
- Medtronic$16K
- Abiomed$15K
- Penumbra, Inc.$11K
- Abbott$5K
- plus $20K from 54 others
Across 63 payments — averaging $1933.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$93K
- Janssen Research & Development, LLC$29K
What the payments were for
- Consulting fees$61,14438%
- Speaking & faculty fees$49,43530%
- Travel & lodging$17,99011%
- Food & beverage$34,20421%
- Education$840%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$71,586
- Edwards SAPIEN 3 Transcatheter Heart Valve$20,446
- Impella$14,069
- Abre$9,941
- Indigo System$9,357
- LifeVest$2,500
- COREVALVE EVOLUT R$2,217
- TandemLife$1,400
- FLOWTRIEVER CATHETER, S$1,172
- CT THROMBECTOMY SYSTEM KIT$1,172
- CoreValve Evolut$1,070
- CVX-300$700
- Micra$681
- Peripheral Orbital Atherectomy System$501
- ENDOCROSS Device$498
- Torus Stent Graft System$498
- Indigo$457
- SAPIEN 3 Ultra RESILIA$455
- Quadra Assura CRT Defibrillator$352
- PASCAL$344
How this compares
$162,857 in reported general payments places this provider in the 90th percentile of 585 interventional cardiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 100 | $123,825 |
| EntrestoSacubitril/Valsartan | 48 | $78,635 |
| JardianceEmpagliflozin | 35 | $53,914 |
| BrilintaTicagrelor | 38 | $36,466 |
| XareltoRivaroxaban | 34 | $34,421 |
| Repatha SureclickEvolocumab | 14 | $19,514 |
| FarxigaDapagliflozin Propanediol | 11 | $17,873 |
| VascepaIcosapent Ethyl | 13 | $13,860 |
| Ezetimibe | 66 | $3,330 |
| Valsartan | 126 | $3,293 |
| Rosuvastatin Calcium | 125 | $3,270 |
| Atorvastatin Calcium | 225 | $3,034 |
| Metoprolol Succinate | 130 | $1,922 |
| Bumetanide | 22 | $1,015 |
| Carvedilol | 135 | $976 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $92 | $123,825100 claims |
| NovartisEntresto | $609 | $78,63548 claims |
| AstraZenecaBrilinta, Farxiga | $780 | $54,33949 claims |
| Boehringer IngelheimJardiance | $66 | $53,91435 claims |
| Johnson & JohnsonXarelto | $466 | $34,42134 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 585 interventional cardiology providers in California.
Other interventional cardiology in San Diego
- Mitul PatelSan Diego$602K
- Raghava GollapudiSan Diego$499K
- Luke OakleySan Diego$317K
- Justin CoxSan Diego$291K
- Matthew Pricela Jolla$2.3M
- Frederick St GoarMountain View$2.2M
- Saibal KarThousand Oaks$1.1M
- Rahul SharmaStanford$1M
- Puneet KhannaRancho Mirage$1M
- Dennis SheehanRedwood City$900K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.